Worldwide Carcinoembryonic Antigen Market Expected To Reach $ 2.33 Billion By 2020 With A CAGR Of 6.6%

Worldwide Carcinoembryonic Antigen Market Expected To
Reach $ 2.33 Billion By 2020 With A CAGR Of 6.6%
Date: 2016-08-24
Constant technological advancements pertaining to the development of novel biomarkers
which can be used in combination with other biomarkers is expected to boost usage rates
over the forecast period. Furthermore, the increasing prevalence of cancer is expected to
heighten the demand for effective diagnostic tools. According to the WHO estimates in
2012, global cancer incidences were nearly 14.1 million, which include 6.7 million female
patients and 7.4 million male patients. Increasing demand for minimally invasive
diagnostics procedures is also expected to play a vital role in determining market growth.
Key advantages associated with minimally invasive diagnostics procedures include
elevated patient satisfaction levels as they entail minor incision wounds. In addition, these
procedures involve relatively lesser hospital stays and therefore, are economically viable
and involve fewer post procedure complications.
The Carcinoembryonic Antigen market was estimated at USD$ 1.69 billion in 2015, and is
anticipated to reach USD$ 2.33 billion by 2020, expanding at a CAGR of 6.6% between
2016 and 2020.
North America, hinged on the U.S. Carcinoembryonic Antigen market size, is predicted to
lead the segment with estimations of USD 800 million in 2016. Growing awareness about
detecting cancer at an early stage and improved health care services for cancer
therapeutics are anticipated to propel growth. Asia-Pacific region driven by India and China
is targeted to foresee growing prevalence of cancer owing to changes in lifestyle and aging
population in the area. The growth is mainly attributed to improved treatment facilities and
high disposable income. The Asia-Pacific market share can surpass USD 380 million in the
near future.
Colorectal cancer tops the application segment and is expected to foresee growth over the
forecast period. Breast cancer segment is likely to be the most lucrative with estimations
of over USD 460 million at over 7% CAGR during the projected time frame.
Read Full Report:
Joanna | Executive – International Business and partner Relations
E-mail: [email protected] | Tel: 1-510-400-8520
Browse this news: